Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis.
Bronchiectasis is a disease characterized by hypersecretion and retention of mucus requiring physical and pharmacologic treatment. Recently we reported that inhalation of dry powder mannitol markedly increases mucociliary clearance (MCC) in asthmatic and in healthy subjects (Daviskas, E., S. D. Anderson, J. D. Brannan, H. K. Chan, S. Eberl, and G. Bautovich. 1997. Inhalation of dry-powder mannitol increases mucociliary clearance. Eur. Respir. J. 10:2449-2454). In this study we investigated the effect of mannitol on MCC in patients with bronchiectasis. Eleven patients 40 to 62 yr of age inhaled mannitol (approximately 300 mg) from a Dinkihaler. MCC was measured over 90 min, in the supine position, on three occasions involving: mannitol or control or baseline, using a radioaerosol technique. On the control day patients reproduced the breathing maneuvers and the number of coughs induced by the mannitol. Mannitol significantly increased MCC over the 75 min from the start of the intervention compared with control and baseline in the whole right lung, central, and intermediate region. Mean (+/- SEM) clearance with mannitol was 34.0 +/- 5.0% versus 17.4 +/- 3.8% with control and 11.7 +/- 4.4% with baseline in the whole right lung (p < 0.0001). The mean number of coughs induced by mannitol was 49 +/- 11. In conclusion, inhalation of dry powder mannitol increased clearance of mucus and thus has the potential to benefit patients with bronchiectasis.
Daviskas
E
E
Departments of Respiratory and Pet and Nuclear Medicine, Royal Prince Alfred Hospital, Camperdown, Australia.
Anderson
S D
SD
Eberl
S
S
Chan
H K
HK
Bautovich
G
G
D000280:Administration, Inhalation; D000328:Adult; D000336:Aerosols; D001987:Bronchiectasis / Q000188:drug therapy* / Q000503:physiopathology*; D003371:Cough / Q000453:epidemiology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008353:Mannitol / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D009079:Mucociliary Clearance / Q000187:drug effects*; D011208:Powders
D000336:Aerosols; D011208:Powders; D008353:Mannitol